Clobazam and Metabolite, Quantitative, Serum or Plasma
Ordering Recommendation
Use to optimize drug therapy and monitor patient adherence.
New York DOH Approval Status
Specimen Required
Plain red, lavender (K2 or K3EDTA) or pink (K2EDTA).
Separate from cells ASAP or within two hours of collection. Transfer 2 mL serum or plasma to an ARUP standard transport tube. (Min: 0.3 mL)
Refrigerated. Also acceptable: Room temperature or frozen.
Gel separator tubes. Hemolyzed specimens.
Ambient: 3 days; Refrigerated: 2 weeks; Frozen: 2 months (Avoid repeated freeze thaw cycles)
Methodology
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Performed
Mon, Wed, Sat
Reported
1-6 days
Reference Interval
Test Number |
Components |
Reference Interval |
---|---|---|
Clobazam | 30-300 ng/mL | |
N-Desmethylclobazam | 300-3000 ng/mL |
Interpretive Data
Clobazam is a benzodiazepine drug indicated for adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients 2 years and older. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. The pharmacokinetics of clobazam are influenced by drug-drug interactions and by poor CYP2C19 metabolism. Adverse effects may include constipation, somnolence, sedation, and skin rash. The concomitant use of clobazam with other central nervous system (CNS) depressants may increase the risk of somnolence and sedation.
Components |
Interpretive Data |
---|---|
Clobazam | Toxic: Greater than 500 ng/mL |
N-Desmethylclobazam | Toxic: Greater than 5000 ng/mL |
Laboratory Developed Test (LDT)
Note
Hotline History
Hotline History
CPT Codes
80339 (Alt code: G0480)
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
3002509 | Clobazam | 3487-6 |
3002510 | N-Desmethylclobazam | 35107-2 |
Aliases
- Onfi
- Sympazan